Policy / Pricing Joint MHRA/NICE pathway ‘benefits industry over patients’ PharmaphorumLSE pharma policy expert contends the MHRA/NICE aligned pathway is weighted towards industry, and calls for an assessment of its impact on the NHS.Read full story pharminent May 14, 2026 (Last updated: May 16, 2026) Pharmaphorum LSE pharma policy expert contends the MHRA/NICE aligned pathway is weighted towards industry, and calls for an assessment of its impact on the NHS. Read full story Post navigation Previous: FDA’s leadership void leaves biotech with renewed ‘uncertainty’Next: Pfizer receives EC approval for Hympavzi to treat haemophilia Related Stories Policy / Pricing Mid-cap biotechs join Trump’s latest round of drug pricing deals pharminent September 1, 2026 Policy / Pricing MFN sparks defiance from Europe’s larger nations, uncertainty among smaller ones pharminent August 27, 2026 Policy / Pricing MFN affecting Swiss medicines access, says Interpharma pharminent August 13, 2026